Mutations in the SARS-CoV-2 RNA dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms

The nucleoside analog remdesivir (RDV) is a Food and Drug Administration (FDA)-approved antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Thus, it is critical to understand factors that promote or prevent RDV resistance. We passaged SARS-CoV-2 in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Stevens, Laura J., Pruijssers, Andrea J., Lee, Hery W., Gordon, Calvin J., Tchesnokov, Egor P., Gribble, Jennifer, George, Amelia S., Hughes, Tia M., Lu, Xiaotao, Li, Jiani, Perry, Jason K., Porter, Danielle P., Cihlar, Tomas, Sheahan, Timothy P., Baric, Ralph S., Götte, Matthias, Denison, Mark R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097878/
https://www.ncbi.nlm.nih.gov/pubmed/35482820
http://dx.doi.org/10.1126/scitranslmed.abo0718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097878/
https://www.ncbi.nlm.nih.gov/pubmed/35482820
http://dx.doi.org/10.1126/scitranslmed.abo0718

Ejemplares similares